Isoniazid and rifampicin resistance-associated mutations in Mycobacterium tuberculosis isolates from Yangon, Myanmar: Implications for rapid molecular testing

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 4, 2009, Pages 694-701

  Valvatne, Håvard ^a,b   Syre, Heidi ^a,b   Kross, Martijn ^a   Stavrum, Ruth ^a,b   Ti, Ti ^c   Phyu, Sabai ^d   Grewal, Harleen M S ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c National TB Programme   (Myanmar)

^d NOVARTIS INSTITUTE FOR TROPICAL DISEASES   (Singapore)

Author keywords

Drug susceptibility; Molecular characterization; TB

Indexed keywords

BACTERIAL PROTEIN; ISONIAZID; KATG PROTEIN; PROTEIN AHPC; PROTEIN INHA; PROTEIN OXYR; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CODON; CONTROLLED STUDY; GENE MUTATION; GENOTYPE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROMOTER REGION; SEQUENCE ANALYSIS;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; BACTERIAL TYPING TECHNIQUES; CATALASE; CLUSTER ANALYSIS; DRUG RESISTANCE, BACTERIAL; GENOTYPE; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; MYANMAR; MYCOBACTERIUM TUBERCULOSIS; OXIDOREDUCTASES; POINT MUTATION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROMOTER REGIONS, GENETIC; RIFAMPIN; SEQUENCE ANALYSIS, DNA; TUBERCULOSIS;

EID: 70349440648     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp292     Document Type: Article

References (35)

1. World Health Organization/International Union Against Tuberculosis and Lung Disease. Anti-tuberculosis drug resistance in the world. Fourth Global Report. WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance, 2002-2007. WHO/HTM/TB/2008.394. Geneva: WHO, 2008.
2. World Health Organization. Global tuberculosis control: Surveillance, planning, financing. WHO Report 2008. WHO/HTM/TB/2008.393. Geneva: WHO, 2008.
3. Ti T, Mar TT, Maung W et al. National anti-tuberculosis drug resistance survey, 2002, in Myanmar. Int J Tuberc Lung Dis 2006; 10: 1111-6.
4. Phyu S, Lwin T, Ti T et al. Drug-resistant tuberculosis in Yangon, Myanmar. Scand J Infect Dis 2005; 37: 846-51.
5. Murray PR, Baron EJ, Pfaller MA et al. Antimycobacterial agents and susceptibility test. In: Master RN, ed. Manual of Clinical Microbiology, Seventh Edition. Washington, DC: American Society for Microbiology, 1999; 1601-23.
6. World Health Organization. Molecular line probe assays for rapid screening of patients at risk of multidrug resistant tuberculosis (MDR-TB). Policy Statement, 2008. http://www.who.int/tb/dots/laboratory/ line_probe_assays/en/index.html.
7. Mokrousov I, Narvskaya O, Otten T et al. High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from northwestern Russia, 1996 to 2001. Antimicrob Agents Chemother 2002; 46: 1417-24.
8. Ramaswamy S, Musser JM. Molecular genetic basic of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998; 79: 3-29.
9. Cavusoglu C, Hilmioglu S, Generi S et al. Characterization of rpoB mutations in rifampin-resistant clinical isolates of Mycobacterium tuberculosis from Turkey by DNA sequencing and line probe assay. J Clin Microbiol 2002; 40: 4435-8.
10. Rossau R, Traore H, De Beenhouwer H et al. Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of Mycobacterium tuberculosis complex and its resistance to rifampin. Antimicrob Agents Chemother 1997; 41: 2093-8.
11. Hain Lifescience, GmbH. GenoType® MTBDRPlus, version 1.0. http://www.hain-lifescience.de/en/downloads/microbiology.html (14 January 2009, date last accessed).
12. Hazbon MH, Brimacombe M, Bobadilla del Valle M et al. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2006; 50: 2640-9.
13. van Soolingen D, de Haas P, van Doorn R et al. Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands. J Infect Dis 2000; 182: 1788-90.
14. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual, Second Edition. Cold Spring Harbor: Cold Spring Laboratory, 1989.
15. Mphahlele M, Syre H, Valvatne H et al. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J Clin Microbiol 2008; 46: 3459-64.
16. Silva MS, Senna SG, Ribeiro MO et al. Mutations in katG, inhA, and ahpC genes of Brazilian isoniazid-resistant isolates of Mycobacterium tuberculosis. J Clin Microbiol 2003; 41: 4471-4.
17. De Beenhouwer H, Lhiang Z, Jannes G et al. Rapid detection of rifampicin resistance in sputum and biopsy specimens from tuberculosis patients by PCR and line probe assay. Tuber Lung Dis 1995; 76 425-30.
18. Groenen PM, Bunschoten AE, van Soolingen D et al. Nature of DNA polymorphism in the direct repeat cluster of Mycobacterium tuberculosis; application for strain differentiation by a novel typing method. Mol Microbiol 1993; 10: 1057-65.
19. Phyu S, Stavrum R, Lwin T et al. Predominance of Mycobacterium tuberculosis EAI and Beijing lineages in Yangon, Myanmar. J Clin Microbiol 2009; 47: 335-44.
20. van Embden JD, Cave MD, Crawford JT et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 1993; 31: 406-9.
21. Kam KM, Yip WC, Tse WL et al. Utility of mycobacterial interspersed repetitive unit typing for differentiating multidrug-resistant Mycobacterium tuberculosis isolates of the Beijing family. J Clin Microbiol 2005; 43: 306-13.
22. Brudey K, Driscoll JR, Rigouts L et al. Mycobacterium tuberculosis complex genetic diversity: Mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiol 2006; 6: 23.
23. Ahmad S, Mokaddas E, Fares E. Characterization of rpoB mutations in rifampin-resistant clinical Mycobacterium tuberculosis isolates from Kuwait and Dubai. Diagn Microbiol Infect Dis 2002; 44: 245-52.
24. Mikhailovich V, Lapa S, Gryadunov D et al. Identification of rifampin-resistant Mycobacterium tuberculosis strains by hybridization, PCR, and ligase detection reaction on oligonucleotide microchips. J Clin Microbiol 2001; 39: 2531-40.
25. Herrera L, Jiménez S, Valverde A et al. Molecular analysis of rifampicin-resistant Mycobacterium tuberculosis isolated in Spain (1996-2001). Description of new mutations in the rpoB gene and review of the literature. Int J Antimicrob Agents 2003; 21: 403-8.
26. Ramaswamy S, Dou S, Rendon A et al. Genotypic analysis of multidrug-resistant Mycobacterium tuberculosis isolates from Monterrey, Mexico. J Med Microbiol 2004; 53: 107-13.
27. Heep M, Brandstätter B, Rieger U, Lehn N et al. Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates. J Clin Microbiol 2001; 39: 107-10.
28. Quan S, Venter H, Dabbs ER. Ribosylative inactivation of rifampin by Mycobacterium smegmatis is a principal contributor to its low susceptibility to this antibiotic. Antimicrob Agents Chemother 1997; 41: 2456-60.
29. Cohen T, Sommers B, Murray M. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect Dis 2003; 3: 13-21.
30. van Doorn HR, de Haas PE, Kremer K et al. Public health impact of isoniazid-resistant Mycobacterium tuberculosis strains with a mutation at amino-acid position 315 of katG: A decade of experience in The Netherlands. Clin Microbiol Infect 2006; 8: 769-75.
31. Bakonyte D, Baranauskaite A, Cicenaite J et al. Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis clinical isolates in Lithuania. Antimicrob Agents Chemother 2003; 47: 2009-11.
32. Rinder H, Thomschke A, Rüsch-Gerdes S et al. Significance of ahpC promoter mutations for the prediction of isoniazid resistance in Mycobacterium tuberculosis. Eur J Clin Microbiol Infect Dis 1998; 17: 508-11.
33. Kiepiela P, Bishop KS, Smith AN et al. Genomic mutations in the katG, inhA and ahpC genes are useful for the prediction of isoniazid resistance in Mycobacterium tuberculosis isolates from Kwazulu Natal, South Africa. Tuber Lung Dis 2000; 80: 47-56.
34. Rawat R, Whitty A, Tonge PJ. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: Adduct affinity and drug resistance. Proc Natl Acad Sci USA 2003; 100: 13881-6.
35. Ohno H, Koga H, Kohno S et al. Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan. Antimicrob Agents Chemother 1996; 40: 1053-6.